Revolution Medicines, Inc. Fair Value Adjustment of Warrants
Revolution Medicines, Inc. (RVMD) reported Fair Value Adjustment of Warrants of $151.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-05
- Revolution Medicines, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was $151.03M, a 3199.06% increase year-over-year.
- Revolution Medicines, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was $15.79M.
- Revolution Medicines, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $12.63M, a 5639.55% increase year-over-year.
- Revolution Medicines, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $592.00K, a 53.35% decline year-over-year.
- Revolution Medicines, Inc. fair value adjustment of warrants for fiscal 2025 was $15.36M.
- Revolution Medicines, Inc. fair value adjustment of warrants for fiscal 2024 was -$4.32M, a 3859.13% decline from fiscal 2023.
- Revolution Medicines, Inc. fair value adjustment of warrants for fiscal 2023 was $115.00K.
- Revolution Medicines, Inc. fair value adjustment of warrants for fiscal 2022 was $0.00.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $151.03M 10-Q · filed 2026-08-05 | $166.82M 10-Q · filed 2026-08-05 | $179.45M derived: sum of 3 quarters · filed 2026-08-05 | $180.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $15.79M 10-Q · filed 2026-05-06 | $28.41M derived: sum of 2 quarters · filed 2026-05-06 | $29.01M derived: sum of 3 quarters · filed 2026-05-06 | $33.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $12.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.22M derived: sum of 2 quarters · filed 2026-02-25 | $17.80M derived: sum of 3 quarters · filed 2026-08-05 | $15.36M 10-K · filed 2026-02-25 |
| 2025-09-30 | $592.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.17M derived: sum of 2 quarters · filed 2026-08-05 | $2.73M 10-Q · filed 2025-11-05 | $2.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.58M 10-Q · filed 2026-08-05 | $2.14M 10-Q · filed 2026-08-05 | $2.36M derived: sum of 3 quarters · filed 2026-08-05 | $3.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.44M 10-Q · filed 2026-05-06 | -$2.22M derived: sum of 2 quarters · filed 2026-05-06 | -$950.00K derived: sum of 3 quarters · filed 2026-05-06 | -$2.86M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.49M derived: sum of 2 quarters · filed 2026-02-25 | -$418.00K derived: sum of 3 quarters · filed 2026-02-25 | -$4.32M 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$638.00K derived: sum of 2 quarters · filed 2025-11-05 | -$4.54M 10-Q · filed 2025-11-05 | -$4.43M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$5.81M 10-Q · filed 2025-08-06 | -$5.70M derived: sum of 3 quarters · filed 2026-02-25 | -$5.70M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$3.90M 10-Q · filed 2025-05-07 | -$3.79M derived: sum of 2 quarters · filed 2026-02-25 | -$3.79M derived: sum of 3 quarters · filed 2026-02-25 | -$3.79M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $115.00K derived: sum of 2 quarters · filed 2026-02-25 | $115.00K derived: sum of 3 quarters · filed 2026-02-25 | $115.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |